Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled single ascending dose escalation study
intended to assess the safety, pharmacokinetics and efficacy of single treatment of SL-1002
in patients with mild to severe limb spasticity. The study will enroll 4 cohorts of 8
patients per cohort for a total of 32 patients. Patients will be randomized to receive either
SL-1002 or placebo in a 3:1 ratio. The study period will be up to 26 weeks inclusive of a
screening period of up to 2 weeks.